Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture

Bone

Volumn 64, Issue , 2014, Pages 281-287

  Rauner, M ^a   Foger Samwald U ^b   Kurz, M F ^b   Brunner Kubath C ^b   Schamall, D ^b   Kapfenberger, A ^b   Varga, P ^c,h,i   Kudlacek, S ^d   Wutzl, A ^b   Hoger H ^b   Zysset, P K ^c   Shi, G P ^e   Hofbauer, L C ^a,f   Sipos, W ^g   Pietschmann, P ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^d KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^g UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adipocyte; Bone remodeling; Cathepsin S; Osteoblast; Osteoclast

Indexed keywords

CATHEPSIN S; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCALCIN; PROCOLLAGEN; TELOPEPTIDE; TYPE 1 PROCOLLAGEN AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; CATHEPSIN;

ADIPOCYTE; ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MICROARCHITECTURE; BONE STRUCTURE; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HISTOLOGY; LIPID METABOLISM; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN BLOOD LEVEL; TRABECULAR BONE; WILD TYPE; ANIMAL; BONE; BONE REMODELING; CYTOLOGY; KNOCKOUT MOUSE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; ULTRASTRUCTURE;

ADIPOCYTES; ANIMALS; BONE AND BONES; BONE REMODELING; CATHEPSINS; CELL DIFFERENTIATION; MICE; MICE, KNOCKOUT; OSTEOBLASTS; REAL-TIME POLYMERASE CHAIN REACTION; X-RAY MICROTOMOGRAPHY;

EID: 84900009594     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.022     Document Type: Article

References (44)

1. Riese R.J., Mitchell R.N., Villadangos J.A., Shi G.P., Palmer J.T., Karp E.R., et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1999, 101:2351-2363.
2. Shi G.P., Munger J.S., Meara J.P., Rich D.H., Chapman H.A. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992, 267:7258-7262.
3. Pozgan U., Caglic D., Rozman B., Nagase H., Turk V., Turk B. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010, 391:571-579.
4. Verrijn Stuart A.A., Schipper H.S., Tasdelen I., Egan D.A., Prakken B.J., Kalkhoven E., et al. Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. J Clin Endocrinol Metab 2012, 97:463-472.
5. Naour N., Rouault C., Fellahi S., Lavoie M.E., Poitou C., Keophiphath M., et al. Cathepsins in human obesity: changes in energy balance predominantly affect cathepsin s in adipose tissue and in circulation. J Clin Endocrinol Metab 2010, 95:1861-1868.
6. Jobs E., Risérus U., Ingelsson E., Sundström J., Jobs M., Nerpin E., et al. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men. Diabetes Care 2013, 36:163-165.
7. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10:207-217.
8. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol 2005, 174:1729-1737.
9. Baugh M., Black D., Westwood P., Kinghorn E., McGregor K., Bruin J., et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 2011, 36:201-209.
10. Saegusa K., Ishimaru N., Yanagi K., Arakaki R., Ogawa K., Saito I., et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002, 110:361-369.
11. Pietschmann P., Foger-Samwald U., Sipos W., Rauner M. The role of cathepsins in osteoimmunology. Crit Rev Eukaryot Gene Expr 2013, 23:11-26.
12. Thurmond R.L., Sun S., Karlsson L., Edwards J.P. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs 2005, 6:473-482.
13. Taleb S., Cancello R., Clément K., Lacasa D. Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology 2006, 147:4950-4959.
14. Taleb S., Lacasa D., Bastard J.P., Poitou C., Cancello R., Pelloux V., et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J 2005, 19:1540-1542.
15. Taleb S., Cancello R., Poitou C., Rouault C., Sellam P., Levy P., et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab 2006, 91:1042-1047.
16. Stern I., Marc J., Kranjec I., Zorman D., Cerne A., Cerne D. Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis. Clin Biochem 2010, 43:1427-1430.
17. Liu J., Ma L., Yang J., Ren A., Sun Z., Yan G., et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006, 186:411-419.
18. de Nooijer R., Bot I., von der Thüsen J.H., Leeuwenburgh M.A., Overkleeft H.S., Kraaijeveld A.O., et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:188-194.
19. Rodgers K.J., Watkins D.J., Miller A.L., Chan P.Y., Karanam S., Brissette W.H., et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006, 26:851-856.
20. Sukhova G.K., Zhang Y., Pan J.H., Wada Y., Yamamoto T., Naito M., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 111:897-906.
21. Samokhin A.O., Lythgo P.A., Gauthier J.Y., Percival M.D., Brömme D. Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol 2010, 56:98-105.
22. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
23. Enomoto H., Furuichi T., Zanma A., Yamana K., Yoshida C., Sumitani S., et al. Runx2 deficiency in chondrocytes causes adipogenic changes in vitro. J Cell Sci 2004, 117:417-425.
24. Hong J.H., Hwang E.S., McManus M.T., Amsterdam A., Tian Y., Kalmukova R., et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
25. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., Macdougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007, 282:14515-14524.
26. Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M., et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007, 9:1273-1285.
27. Ha E., Dieudonné F.X., Saidak Z., Marty C., Brun J., Nascimento S.D., et al. N-Cadherin/Wnt interaction controls bone marrow mesenchymal cell fate and bone mass during aging. J Cell Physiol 2014, [in press].
28. Chan G.K., Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002, 48:62-71.
29. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
30. Rauner M., Thiele S., Sinningen K., Winzer M., Salbach-Hirsch J., Gloe I., et al. Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis. Endocrinology 2013, 154:3719-3728.
31. Thiele S., Ziegler N., Tsourdi E., De Bosscher K., Tuckermann J.P., Hofbauer L.C., et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012, 27:2242-2250.
32. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
33. Rauner M., Sipos W., Goettsch C., Wutzl A., Foisner R., Pietschmann P., et al. Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res 2009, 24:78-86.
34. Cheng X.W., Shi G.P., Kuzuya M., Sasaki T., Okumura K., Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125:1551-1562.
35. Caglič D., Repnik U., Jedeszko C., Kosec G., Miniejew C., Kindermann M., et al. The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes. Biol Chem 2013, 394:307-316.
36. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998, 95:13453-13458.
37. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999, 14:1654-1663.
38. Chapurlat R.D. Odanacatib for the treatment of postmenopausal osteoporosis. Expert Opin Pharmacother 2014, 15:559-564.
39. Sipos W., Zysset P., Kostenuik P., Mayrhofer E., Bogdan C., Rauner M., et al. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. Horm Metab Res 2011, 43:944-949.
40. Han J., Luo T., Gu Y., Li G., Jia W., Luo M. Cathepsin K regulates adipocyte differentiation: possible involvement of type I collagen degradation. Endocr J 2009, 56:55-63.
41. Funicello M., Novelli M., Ragni M., Vottari T., Cocuzza C., Soriano-Lopez J., et al. Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS One 2007, 2:e683.
42. Yang M., Zhang Y., Pan J., Sun J., Liu J., Libby P., et al. Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol 2007, 9:970-977.
43. Mraz M., Lacinova Z., Drapalova J., Haluzikova D., Horinek A., Matoulek M., et al. The effect of very-low-calorie diet on mRNA expression of inflammation-related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2011, 96:E606-E613.
44. Guzik T.J., Mangalat D., Korbut R. Adipokines: novel link between inflammation and vascular function?. J Physiol Pharmacol 2006, 57:505-528.